


Product Details

| | | | |
|------------------------|---|---------------------------|-----------------|
| Product name: | Anti-human DLL4 (navicixizumab Biosimilar) | SKU: | BIO00151SM |
| Target Name: | DLL4 | Size: | 1 mg/5 mg/20 mg |
| Target Uniprot: | Q9NR61 | Concentration: | Lyophilized |
| Clone#: | navicixizumab | Isotype: | Human IgG2SA |
| Reactivity: | Human | Calculated M.W.: | 146.17 kDa |
| Application: | ELISA, Bioactivity: FACS, Functional assay, Research in vivo | Endotoxin: | <0.001 EU/ug |
| Formulation: | 0.1M Pro, 20mM Arg, pH5.0 | Conjugation: | None |
| Storage: | For long term storage, the produce should be stored at -20° C or lower. | Expression System: | CHO |
| Reconstitution: | Dissolve with sterile ddH2O | Purification: | Protein A |


Data

Purity:SDS-PAGE




Anti-DLL4 (navicixizumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

Purity:SEC-HPLC



The purity of Anti-DLL4 (navicixizumab) is more than 95%, determined by SEC-HPLC.

Bioactivity:ELISA



Immobilized human VEGF165 His at 2 ug/mL can bind Anti-DLL4 (navicixizumab), EC50=0.01191 ug/mL.